LTBP2 and Alzheimer disease: Moreover, consistent with prior studies in humans or animals, LTBP2 (Guo et al., 2024), EGFR (Jayaswamy et al., 2023), APOE (Aslam et al., 2023), TGFBR1 (Kuroda et al., 2020), VGF (Beckmann et al., 2020), NPTXR (Wildsmith et al., 2014), and IGFBP3 (Duron et al., 2012) were associated with the risk of AD.